| | Row | Author, year | Exposure | Outcome definition | Measure of association and explanation | Results | | Gene name | Mutation | Grouping |
| | 1 | Campos-Staffico, 2022 | CYP3A4 | rs35599367 | AA vs. AG vs. GG | Bleeding | HR (95% CI) | 0.891 (0.708 to 1.122) | | CYP3A5 | rs776746 | CC vs. CT vs. TT | 0.943 (0.687 to 1.294) | | CYP2J2 | rs890293 | CC vs. CA vs. AA | 1.131 (0.871 to 1.468) | | ABCG2 | rs2231142 | GG vs. GA vs. AA | 1.055 (0.863 to 1.289) | | ABCB1 | rs4148732 | GG vs. GA vs. AA | 1.096 (0.956 to 1.256) | | C-G-C diplotypes | Homozygous vs. hetero vs. other | 1.027 (0.895 to 1.179) |
| | 2 | Gouin-Thibault, 2016 | ABCB1 | rs2677-3435 | CC | AUC | Mean (percentage coefficient of variation) | 1802, 42 | | rs2677-3435 | CT | 2238, 43 | | rs2677-3435 | TT | 2078, 50 | | rs2677-3435 | CC | Maximum concentration | 161, 27 | | rs2677-3435 | CT | 190, 31 | | rs2677-3435 | TT | 178, 30 |
| | 3 | Lähteenmäki, 2021 | ABCB1 | rs1045642 | CC vs. AA and AC | Bleeding | HR (95% CI) | 0.84 (0.37 to 1.91) | | rs2032582 | AA vs. AC and CC | 1.06 (0.33 to 3.43) | | rs1128503 | AA vs. AG and GG | 1.03 (0.50 to 2.12) | | rs1045642 | CC vs. AA and AC | Thromboembolic event | 0.42 (0.18 to 0.98) | | rs2032582 | AA vs. AC and CC | 0.50 (0.23 to 1.08) | | rs1128503 | AA vs. AG and GG | 0.82 (0.36 to 1.89) |
| | 4 | Lenoir, 2022 | ABCB1 | rs1128503 | AG vs. AA | AUC | Mean (95% CI) | −46.50 (−163.59 to 70.59) | | GG vs. AA | 21.46 (−125.94 to 168.86) | | rs1045642 | AC vs. CC | −51.69 (−170.92 to 67.54) | | AA vs. CC | −71.90 (−161.27 to 17.46) | | rs2032582 | GT vs. GG | 56.52 (−75.24 to 188.29) | | TT vs. GG | 54.86 (−96.09 to 205.81) |
| | 5 | Nakagawa, 2017 | CYP3A5 | rs776746 | TT | Maximum concentration | Mean (95% CI) | 4.77 (3.83 to 7.36) | | TC | 3.58 (2.21 to 5.13) | | CC | 2.99 (1.94 to 5.34) | | ABCB1 | rs1045642 | AA | 2.87 (2.45 to 5.14) | | AC | 3.43 (1.89 to 5.72) | | CC | 3.76 (2.12 to 5.14) | | rs2032582 | GG | 4.17 (2.16 to 6.05) | | GT | 3.17 (1.31 to 5.11) | | TT | 3.35 (2.45 to 5.41) | | rs1128503 | AA | 4.37 (2.49 to 4.91) | | AG | 3.09 (2.11 to 5.72) | | GG | 3.06 (2.18 to 5.30) | | ABCG2 | rs2231142 | GG | 3.35 (2.25 to 5.14) | | GA | 3.47 (1.88 to 5.39) | | AA | 1.89 (0.99 to 3.49) | | CYP2J2 | rs890293 | CC | 3.26 (2.11 to 5.14) | | CA | 4.31 (2.39 to 8.60) | | AA | NR |
| | 6 | Sychev, 2019 | ABCB1 | rs1045642 | AA | AUC | Mean, to value | 150.4 | | AC | 121, 0.306 | | CC | 128, 0.857 | | rs4148738 | CC | 142.2 | | CA | 120.8, 0.391 | | AA | 131.3, 0.987 | | CYP3A4 | rs35599367 | GG | 123.5 | | GA | 118.2, 0.716 | | AA | NR | | CYP3A5 | rs776746 | TT | 193.3 | | TC | 121.0, 0.217 | | CC | NR |
| | 7 | Sychev, 2022 | ABCB1 | rs1045642 | AA | Maximum concentration | Mean (95% CI) | 57.7 (23.3 to 75.8) | | AC | 50.6 (28.3 to 80.6) | | CC | 65.8 (36.4 to 95.7) | | AA | Gastrointestinal bleeding | Number of patients presented with outcome/genotype (%) | 0/22 (0) | | AC | 3/65 (4.6) | | CC | 1/41 (2.4) | | AA | Hematuria | 0/22 (0) | | AC | 6/65 (9.2) | | CC | 9/41 (22) | | AA | Prothrombin time | Mean (95% CI) | 13.3 (12.4 to 14.5) | | AC | 14.0 (12.6 to 14.8) | | CC | 14.2 (13.0 to 16.1) | | rs4148738 | CC | Maximum concentration | Mean (95% CI) | 57.7 (28.3 to 98.0) | | CA | 52.1 (28.4 to 80.4) | | AA | 56.35 (36.3 to 89.1) | | CC | Gastrointestinal bleeding | Number of patients presented with outcome/each genotype (%) | 1/37 (2.7) | | CA | 2/63 (3.2) | | AA | 1/28 (3.6) | | CC | Hematuria | 1/37 (2.7) | | CA | 5/63 (7.9) | | AA | 9/28 (32.1) | | CC | Prothrombin time | Mean (95% CI) | 13.4 (12.4 to 14.7) | | CA | 14.0 (12.8 to 14.6) | | AA | 14.2 (12.9 to 16.5) |
| | 8 | Wang, 2021 | ABCB1 | rs1045642 | AA | Bleeding | Number of patients in each genotype, presented with bleeding | 22, 3 | | AC | 70, 10 | | CC | 63, 11 | | rs1128503 | AA | 65, 0 | | AG | 63, 10 | | GG | 27, 5 | | rs4148738 | CC | 31, 3 | | CA | 64, 10 | | AA | 60, 11 |
| | 9 | Yoon, 2022 | ABCB1 | rs1045642 | AA vs. AC and CC | Bleeding | OR (%) | 2.44 (1.07 to 5.58) | | APOB | rs693 | TT vs. CC and CT | 6.85 (0.90 to 52.63) | | rs13306198 | GG vs. AA and GA | 3.00 (1.39 to 6.47) |
| | 10 | Zhang, 2023 | ABCB1 | rs4728709 | GG vs. AA and GA | Increase in maximum concentration | Mean (SD) | 47.6% (9.1%) |
|
|
HR, hazard ratio; OR, odds ratio; CI, confidence interval; AUC, area under the plasma concentration-time curve.
|
